首页> 外文期刊>Medicinski Glasnik >Endovascular or open surgical treatment of high-risk patients with infrainguinal peripheral arterial disease and critical limb ischemia
【24h】

Endovascular or open surgical treatment of high-risk patients with infrainguinal peripheral arterial disease and critical limb ischemia

机译:高危患者的血管内或开放手术治疗患有针尖外周血和临界肢体缺血的高危患者

获取原文
获取外文期刊封面目录资料

摘要

Aim To determine preferable type of treatment in our clinical circumstances by following two groups of patients with critical limb ischemia (CLI), who were treated endovascularly and surgically. Methods Research was carried out in the form of a prospective study of 80 patients with CLI and Trans-Atlantic Inter-Society Consensus (TASC) C or D type of arterial disease, with American Society of Anesthesiology (ASA) class III risk, who were randomly divided in two groups as per the treatment they received, surgical and endovascular. Patients were followed during 28 months using clinical examination and Duplex Ultrasound (DUS) in accordance with prescheduled control visits. Results There was a statistical difference between surgical and endovascular group in two years patency (82.5% vs. 55%; p=0.022) but it did not result in the difference in amputation free survival (AFS) (95% vs. 85%; p=0.171) or two-year freedom from major adverse limb events (MALE) (87.5 vs. 77.5; p=0.254). Also, there was no difference in the overall survival of patients (100% vs. 97.5%; p=0.317). Conclusion Initial endovascular treatment is a preferred form of the treatment for selected patient population.
机译:目的是通过继血管内和手术治疗两组患者临床血管缺血(CLI)患者确定我们的临床环境中的优选类型。方法研究是以80例CLI和跨大西洋社会间共识(TASC)C或D型动脉疾病的前瞻性研究的形式进行,患有美国麻醉学会(ASA)III级风险,谁根据它们接受,手术和血管内的治疗随机分为两组。患者在28个月期间使用临床检查和双链运动员(DUS),按照预定的控制访问。结果两年后手术和血管内血管基团之间存在统计学差异(82.5%对55%; P = 0.022),但它没有导致截肢自由生存率(AFS)的差异(95%与85%; P = 0.171)或来自主要不良肢体事件(男性)的两年自由(87.5与77.5; P = 0.254)。此外,患者的整体存活率没有差异(100%vs.97.5%; p = 0.317)。结论初始血管内治疗是对选定患者群体治疗的优选形式。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号